(Also see "Dr Reddy’s Brings In Range Of Mature Novartis Brands In India" - Generics Bulletin, 14 February, 2022.)	With an ‘India First’ strategy previously communicated, Dr Reddy’s Laboratories has brought in several Novartis India Established Medicines. “We intend to evaluate capabilities to maintain business continuity,” the company says.
(Also see "It’s Deal Time: Aurobindo on M&A, Divestment Path" - Scrip, 11 February, 2022.)	What value do PE funds see in Aurobindo Pharma’s injectables business as the company looks for a partner? Why is Aurobindo looking for acquisitions in India as it sets a domestic revenue target of $133m in three years from the formulations business? Scrip takes a look.
(Also see "China's First Biotech M&A Deal In 2022 Signals Busy Season Ahead?" - Scrip, 10 February, 2022.)	CSPC acquires a little-known Guangzhou biotech to kick-start China's pharma sector consolidation in 2022, a key goal outlined in the country's recent 14th Five-Year Plan.
(Also see "China Plans To Speed Up Pharma Consolidation By 2025" - Scrip, 8 February, 2022.)	China's new five-year plan for the pharma sector calls for closer collaboration between large and small domestic pharma companies, not only for products and technologies but also capital. However, it remains to be seen which specific measures government agencies will take to achieve the broad goals.
(Also see "Questions Remain For Samsung Bioepis Post-Biogen" - Generics Bulletin, 8 February, 2022.)	In exclusive comments made to Generics Bulletin, Samsung Biologics has acknowledged that it has yet to decide on several aspects of Samsung Bioepis’ management, structure and strategic focus once Biogen completes the sale of its stake in the biosimilars joint venture to its partner.
(Also see "Dr Reddy’s Steps Into 'Must-Be' Medical Cannabis Segment With German Deal" - Scrip, 4 February, 2022.)	Dr. Reddy’s enters high-potential medical cannabis fray with the acquisition of Nimbus Health in Germany. The segment has seen a flurry of activity over the recent past, including the $7.2bn acquisition of pioneer GW Pharmaceuticals.
(Also see "India's Mankind Licenses Entresto From Novartis, Acquires Panacea’s Brands" - Scrip, 3 February, 2022.)	Mankind Pharma has licensed Novartis’ heart failure therapy Entresto in India, executive chairman Ramesh Juneja tells Scrip. The privately-owned company has also acquired the generics business of Panacea in India and Nepal for over $255m.
(Also see "Lupin’s Neulasta Biosimilar Set For MENA With Axantia Deal" - Generics Bulletin, 1 February, 2022.)	Awaiting US FDA action for its proposed biosimilar to Neulasta, Lupin has out-licensed rights for the product to another set of territories following a recent deal covering Brazil.
(Also see "Acquisitions, Mix-Match Sputnik Light Booster On Dr Reddy’s Menu" - Scrip, 31 January, 2022.)	Dr. Reddy’s indicates it is actively pursuing acquisitions, likely involving relatively smaller assets, across several key markets on the back of a “healthy” balance sheet. It is also progressing plans to position Russian COVID-19 vaccine Sputnik Light as a booster, which it believes could potentially be “part of life” hereon.
(Also see "JB Chemicals Acquires Several Sanzyme Brands" - Generics Bulletin, 28 January, 2022.)	JB Chemicals has purchased a number of leading brands from Sanzyme, which it plans to scale up and institutionalize within India. The transaction, worth over $80m, is expected to close within the next two weeks.
(Also see "GSK India Chief On Pandemic Decisions, Refreshing The Portfolio" - Scrip, 28 January, 2022.)	GSK India managing director Sridhar Venkatesh outlines how the company navigated pandemic-related turbulence and “stuck its neck out” to ensure uninterrupted supplies of key drugs. The executive also discusses launch prospects for products including Xevudy in India and an intent to “refresh” the company’s vaccines portfolio.
(Also see "Bioepis JV Sale To Provide Needed Cash To Biogen" - Scrip, 28 January, 2022.)	Biogen may find itself with new business options after agreeing to sell its stake in the Samsung Bioepis biosimilars joint venture for up to $2.3bn.
(Also see "Lotus To Commercialize Glenmark’s Ryaltris Nasal Spray In SE Asia" - Generics Bulletin, 24 January, 2022.)	Glenmark is set to roll out its allergic rhinitis nasal spray Ryaltris in three South East Asian countries following an exclusive licensing agreement with Lotus. The company expects Ryaltris to have a significant role to play in its growth over the coming years.

Asia Deal Watch: SV Investment And Orange Grove Will Team Up On New Company Effort

More from Deal Watch

More from Deals